By Deena Beasley Oct 7 (Reuters) – Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Updates for close) KUALA LUMPUR, Oct 7 (Reuters) - Malaysian palm oil futures dropped for…
Oct 7 (OPTA) - Scoreboard at stumps on the first day of match 1 between…
VIDEO SHOWS: ROUND OF 16 HIGHLIGHTS FROM CHINA OPEN - A WTA 1000 TOURNAMENT -…
LONDON, Oct 7 (Reuters) - The US 30-year bond yield hit a fresh 24 year…
By Wen-Yee Lee TAIPEI, Oct 7 (Reuters) - A Taiwan union representing workers at Micron…
Oct 7 (Reuters) - United Parcel Service on Wednesday said it is hiring 100,000 seasonal…